Bioactivities of Chitosan and Its Derivatives - Chitosan Based Hydrogels: Functions and Applications - page 175

234. Hsiang, Y. H. and Liu, L. F. 1988. Identification of mammalian topoisomerase I as an intracel-
lular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726.
235. Garcia-Carbonero, R. and Supko, J. G. 2002. Current perspectives on the clinical experience,
pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641-661.
236. Oberlies, N. H. and Kroll, D. J. 2004. Camptothecin and taxol: historic achievements in natural
products research. J Nat Prod 67: 129-135.
237. Sriram, D., Yogeeswari, P., Thirumurugan, R., and Bal, T. R. 2005. Camptothecin and its ana-
logues: a review on their chemotherapeutic potential. Nat Prod Res 19: 398-412.
238. Hwang, H. Y., Kim, I. S., Kwon, I. C., and Kim, Y. H. 2008. Tumor target ability and antitumor
effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control
Release 128: 23-31.
239. Martin, L., Wilson, C. G., Koosha, F., Tetley, L., Gray, A. I., Senel, S., and Uchegbu, I. F. 2006.
The release of model macromolecules may be controlled by the hydrophobicity of palmitoyl
glycol chitosan hydrogels. J Control Release 80: 87-100.
240. Martin, L., Wilson, C. G., Koosha, F., and Uchegbu, I. F. 2003. Sustained buccal delivery of the
hydrophobic drug denbufylline using physical cross-linked palimitoylglycolchitosan hydro-
gels. Eur J Pharm Biopharm 55: 35-45.
241. Fujita, M., Ishihara, M., Shimizu, M., Obara, K., Ishizuka, T., Saito, Y., Yara, H., Morimoto, Y.,
Takase, B., Matsui, T., Kikuchi, M., and Maehara, T. 2004. Vascularization in vivo caused by the
controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant
heparin hydrogel. Biomaterials 25: 699-706.
242. Ishihara, M., Obara, K., Ishizuka, T., Fujita, M., Sato, M., Masuoka, K., Saito, Y., Yura, H., Matsui,
T., Hattori, H., Kikuchi, M., and Kurita, A. 2003. Controlled release of fibroblast growth factors
and heparin from photocross-linked chitosan hydrogels and subsequent effect on in vivo vascu-
larization. J Biomed Mater Res 64A: 551-559.
243. Obara, K., Ishihara, M., Ozeki, Y., Ishizuka, T., Hayashi, T., Nakamura, S., Saito, Y., Yura, H.,
Matsui, T., Hattori, H., Takase, B., and Maehara, T. 2005. Controlled release of paclitaxel from
photocross-linked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth
in mice. J Control Release 110: 79-89.
244. Ishihara, M., Nakamura, S., Masuoka, K., Takase, B., Morimoto, Y., and Maehara, T. 2006.
Chitosan hydrogel as a drug delivery carrier to control angiogenesis. J Artif Organs 9: 8-16.
245. Carreno-Gomez, B. and Duncan, R. 1997. Evaluation of the biological properties of soluble chi-
tosan and chitosan microspheres. Int J Pharm 148: 231-240.
246. Murata, J., Saiki, I., Makabe, T., Tsuta, Y., Tokura, S., and Azuma, I. 1991. Inhibition of tumor-
induced angiogenesis by sulfated chitin derivative. Cancer Res 51: 22-26.
247. Murata, J., Saiki, I., Nishimura, S., Nishi, N., Tokura, S., and Azuma, I. 1989. Inhibitory effect of
chitin heparinoids on the lung metastasis of B16-B16 melanoma. Jpn J Cancer Res 80: 866-872.